Dabigatran, whose brand name is Pradaxa, is approved to prevent blood clots caused by irregular heartbeat called atrial fibrillation, Newsmax Health reports.
The drug was being tested in a late-stage study to prevent deep vein thrombosis, or blood clots in the deep veins of the legs, and pulmonary embolism, or clots in the lungs.
Dabigatran is awaiting U.S. approval for the broader use.
Innovative Spray Developed to Treat Rhinitis Caused by Overuse of Nasal Decongestants
New Experimental Treatment Burns Fat While Preserving Muscle in Obesity and Diabetes Study
What Causes Food Poisoning? Symptoms, Treatment and Prevention Tips
Study: Singing Therapy May Be More Effective Than Breathing Exercises for Chronic Belching
Microdosing GLP-1 weight-loss drugs: Experts urge caution despite growing trend
Fentanyl, Oxycodone, and Morphine: Study Identifies the Highest-Risk Opioid Painkillers
make preferable